Anzeige
Erschienen in:
01.10.2014 | Original Research Article
Anticholinergic Medications: An Additional Contributor to Cognitive Impairment in the Heart Failure Population?
Erschienen in: Drugs & Aging | Ausgabe 10/2014
Einloggen, um Zugang zu erhaltenAbstract
Background/Objectives
Patients with congestive heart failure (CHF) have a high prevalence of cognitive impairment and the association is multifactorial. In general, the burden of anticholinergic drugs has consistently been shown to be a risk factor for cognitive impairment in the elderly. The aim of this study was to assess the cognitive burden of medications in patients with CHF.
Design
This was a cross-sectional, retrospective, single-center study.
Setting
The study was conducted in an outpatient setting.
Participants
Patients who presented to a comprehensive heart failure clinic during a 1-month period were included.
Measurements
The primary outcomes of interest were mean anticholinergic cognitive burden (ACB) score of all medications and CHF medications (ACB-CHF), calculated based on the ACB Scoring Scale (ACB-SS). The ACB-CHF score was further dichotomized as 0 or 1 (low anticholinergic burden) versus 2 or 3 (high anticholinergic burden).
Results
A total of 182 patients were included. The mean ACB and ACB-CHF scores were 2.4 (range 0–13) and 1.0 (range 0–4), respectively, while 25.8 % of patients had an ACB-CHF score of 2 or 3. There was no association found between ejection fraction in patients with systolic heart failure and the ACB (p = 0.28) or ACB-CHF (p = 0.62) score.
Conclusion
We conclude that patients with CHF have a substantial exposure to anticholinergic medications with adverse cognitive effects. This may be another important contributor to the increased prevalence of cognitive impairment in these patients.